Phosphorylated eIF2α predicts disease-free survival in triple-negative breast cancer patients

Background: Triple-negative breast cancer (TNBC) is defined as tumors without estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression. This cancer is associated with higher rates of recurrence risk when compared to other subtypes of breast cancers. In this study, we aimed to explore the basic clinicopathological characteristics, prognosis, and recurrence patterns of TNBC patients. Methods: In the current study, forty-five TNBC female patients operated on for breast cancer in the General Surgery Clinic of Kayseri City Training and Research Hospital between 2016 and 2021 were included and retrospectively evaluated. Results: The percentage of TNBC was 12% of the 502 breast cancer patients who could access all three pieces of receptor information. The mean age of the patients was 58.9±15.2 years (27-90), and the mean BMI was 30.4±5.17 (21.5-40.6). It was observed that the most common histological subtype was invasive ductal carcinoma, and at the time of diagnosis, 11 patients were stage 1 (24.4%), 31 patients were stage 2 (68.8%), 2 patients were stage 3 (4.4%), and 1 patient was stage 4 (2.2%). During the follow-up period, 11 patients (24,4%) developed metastasis and the most common sites were the brain and bones. The mean time from diagnosis to metastasis was 20.7±5.75 (12-29) months. The 3-year disease-free survival was 62%, and the 3-year overall survival (OS) was 70%. Conclusion: TNBCs are cancers with varying prevalence, poor prognosis, and limited treatment alternatives. The prevalence of TNBC in our center was found to be lower than the literature rates and consistent with the literature, the lymph node stage was related to poor OS and disease free survival (DFS).

Download Full-text

Radiotherapy Can Improve the Disease‐Free Survival Rate in Triple‐Negative Breast Cancer Patients with T1–T2 Disease and One to Three Positive Lymph Nodes After Mastectomy

The Oncologist ◽

10.1634/theoncologist.2012-0233 ◽

2013 ◽

Vol 18 (2) ◽

pp. 141-147 ◽

Cited By ~ 16

Author(s):

Xingxing Chen ◽

Xiaoli Yu ◽

Jiayi Chen ◽

Zhaozhi Yang ◽

Zhimin Shao ◽

...

Keyword(s):

Breast Cancer ◽

Survival Rate ◽

Cancer Patients ◽

Triple Negative ◽

Disease Free Survival ◽

Breast Cancer Patients ◽

Free Survival ◽

Disease Free Survival Rate ◽

Disease Free ◽

Positive Lymph Nodes

Download Full-text

The prognostic importance of triple negative breast cancer: A population based study in India

Journal of Clinical Oncology ◽

10.1200/jco.2009.27.15_suppl.e22219 ◽

2009 ◽

Vol 27 (15_suppl) ◽

pp. e22219-e22219

Author(s):

B. S. Ajaikumar ◽

R. Rao ◽

J. Prabhu ◽

J. D. Kulkarni ◽

P. K ◽

...

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

Regression Analysis ◽

Cancer Patients ◽

Triple Negative ◽

Disease Free Survival ◽

Breast Cancer Patients ◽

Free Survival ◽

Node Status ◽

Disease Free

e22219 Background: Triple-negative (ER-negative, PR-negative, HER2/neu negative) breast cancer has distinct clinical and pathologic features, and is a clinical problem because of its typically high grade, relatively poor prognosis, aggressive behavior and lack of targeted therapies leaving chemotherapy as the mainstay of treatment. This study envisaged to analyse the influence of triple negativity status on survival and disease free survival in prospective cohort of breast cancer patients. Methods: Breast tumors of 215 women aged 30–75, diagnosed from 2004 were tested for ER, PR and HER2 positivity by immunohistochemistry and correlated with clinical outcomes such as recurrence, disease free survival and overall survival using Kaplan Meiers Survival analysis and Coxs regression analysis. The study cohort was followed up for 60 months or until death whichever was earlier. Results: Triple negativity significantly influenced disease free survival (46 ± 3, 41, 52) vs. non triple negative cohort (mean ± SE; 95%CI, 37 ± 2; 32, 40) and log rank = 2.1, p = 0.04. However triple negativity did not influence overall survival in months (56 ± 0; 55, 56) vs. non triple negative cohort (43 ± 1; 42, 45), (log rank = 1.78, p = 0.16). However, the mean disease free survival was (45 ± 7; 32, 58) months for patients >40 years age vs (37 ± 4; 33, 39) for patients < 40 years of age (log rank = 2.87, p =0.02). Stage of disease, node status, grade and menopausal status did not influence disease free survival significantly. However, Cox regression analysis did not predict significant effects of triple negativity on overall survival or disease free survival when controlled for confounding factors such as age, node status, stage etc Conclusions: Our observations suggest that triple negativity can significantly affect progression of breast cancer in Indian breast cancer patients and longer follow up is necessary (10 years) to determine its effects on survival. No significant financial relationships to disclose.

Download Full-text